Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Relationships between the prognostic (± relapses) and the mRNA levels of the seven selected genes in 97 estrogen receptor alpha-positive breast tumors

From: Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma

Gene Tumors without relapses (n = 65) Tumors with relapses (n = 32) P a ROC–AUCb
CYP2A6 1.2 (0.001–9741.1)c 0.8 (0.01–7228.8) NS (0.17) 0.41 (0.29–0.54)d
CYP2B6 56.1 (0.3–1053.1) 14.7 (0.03–249.8) 0.011 0.34 (0.23–0.45)
FMO5 3.9 (0.2–30.1) 1.4 (0.1–23.9) 0.0016 0.30 (0.19–0.41)
GSTM3 2.1 (0.07–12.2) 1.7 (0.09–21.2) NS (0.80) 0.48 (0.35–0.62)
SULT2B1 4.9 (0.2–84.4) 3.5 (0.4–21.0) NS (0.65) 0.47 (0.35–0.59)
NAT1 35.9 (1.6–295.6) 10.0 (1.1–134.1) 0.000047 0.24 (0.14–0.35)
ABCC11 15.9 (0.06–195.5) 16.6 (0.04–461.7) NS (0.60) 0.46 (0.33–0.60)
  1. a P value, Mann–Whitney test; NS, not significant. b Receiver–operating characteristics (ROC)–area under curve (AUC) analysis. c Median (range) of gene mRNA levels. d AUC value (95% confidence interval).